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Purpose: The purpose was to investigate the value of procalcitonin (PCT) kinetics in predicting the appropriate-
ness of empirical antimicrobial treatment in critically ill patients.
Materials and methods: This prospective observational study recruited patients in whom empirical antimicrobial
therapy was started for suspected infection. Biochemical and physiological parameters were measured before
initiating antimicrobials (t0), 8 hourly (t8, t16, t24), and then daily (day2-6). Patients were grouped post hoc into
appropriate (A) and inappropriate (IA) groups.
Results: Of 209 patients, infection was conﬁrmed in 67%. Procalcitonin kinetics were different between the IA
(n = 33) and A groups (n = 108). In the IA group, PCT levels (median [interquartile range]) increased: t0=
2.8 (1.2-7.4), t16= 8.6 (4.8-22.1), t24= 14.5 (4.9-36.1), Pb .05. In the A group, PCT peaked at t16 and started to de-
crease by t24: t0= 4.2 (1.9-12.8), t16= 6.99 (3.4-29.1), t24= 5.2 (2.0-16.7), Pb .05. Receiver operating character-
istic analysis revealed that a PCT elevation greater than or equal to 69% from t0 to t16 had an area under the curve
for predicting inappropriate antimicrobial treatment of 0.73 (95% conﬁdence interval, 0.63-0.83), Pb .001; from t0
to t24, a greater than or equal to 74% increase had an area under the curve of 0.86 (0.77-0.94), Pb .001. Hospital
mortality was 37% in the A group and 61% in the IA group (P= .017).
Conclusions: Early response of PCT in the ﬁrst 24 hours of commencing empirical antimicrobials in critically ill
patients may help the clinician to evaluate the appropriateness of therapy.
© 2016 Elsevier Inc. All rights reserved.1. Introduction
Sepsis remains the leading cause of death among critically ill
patients worldwide [1,2]. It is well documented that delaying appropri-
ate antimicrobial treatment increases mortality [3,4], but empirical
antimicrobials have been proven to be inadequate in almost 30% of
cases [5]. Diagnosing infection and assessing the progress of the94695.
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Procalcitonin (PCT) and C-reactive protein (CRP) are themost common-
ly used biomarkers in the clinical setting, of which PCT seems to have a
better sensitivity and speciﬁcity for differentiating bacterial infection
from nonbacterial systemic inﬂammatory response [6–9]. There is con-
siderable evidence that PCT-guided antimicrobial management consid-
erably reduces antimicrobial use in lower respiratory tract infections,
and it may also shorten the duration of antimicrobial treatment in the
intensive care unit (ICU) [10,11].
However, during the initial phase of treatment, physicians often
have no way of conﬁrming the adequacy of the commenced antimicro-
bials. As PCT is a fast-reacting biomarkerwith a half-life of 24 hours, the-
oretically, it is possible that the early kinetics of PCT, within this ﬁrst 24
hours after commencing empirical antimicrobial therapy, may reﬂect
the efﬁcacy of the treatment. Therefore, our aim was to perform a pro-
spective observational study to investigate the value of PCT kinetics
Fig. 1. Flowchart. t0-24 indicates samplingwithin theﬁrst 24 hours after commencement of
empirical antimicrobials; SAPS II, Simpliﬁed Acute Physiology Score II; SOFA, Sequential
Organ Failure Assessment; LOS, length of stay.
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ateness of empirical antimicrobial treatment in critically ill patients.
2. Methods
2.1. Patient selection
This prospective observational study was undertaken between
October 2012 and October 2013 and was approved by the Regional
and Institutional HumanMedical Biological Research Ethics Committee,
University of Szeged, Hungary (WHO-3005; 19.04.2012, Chairperson
Prof T Wittmann). The investigation was performed at the University
of Szeged (Szeged, Hungary) Albert Szent-Györgyi Health Center in a
27-bed multidisciplinary tertiary ICU. The study was registered at
ClinicalTrials.gov with registration number NCT02294695. Written in-
formed consent was obtained from all subjects or from their relatives.
2.1.1. Inclusion criteria
All patients older than 18 years with suspected infection on admis-
sion or during their stay on the ICUwere screened for eligibility. Patients
were enrolled when the attending physician suspected infection and
empirical antimicrobial therapy was started.
2.1.2. Exclusion criteria
The exclusion criteria were as follows: age less than 18 years, antimi-
crobial therapywithin 48 hours, conditions that have been shown to inter-
fere with the inﬂammatory response such as acute renal replacement
therapy in the ﬁrst 24 hours [12] and cardiopulmonary resuscitation
[13], patientswith end-stage diseases, and immunocompromisedpatients.
2.2. Subgroups and deﬁnitions
Diagnosis of infection and appropriateness of the empirical antimicro-
bials were established based on recommendations [14], clinical parame-
ters, and biochemical and microbiological results evaluated by 2 experts
blinded for the PCT data apart from the ﬁrst PCT result: an infectologist
(EH) and an intensivist (JF). Patients were then grouped into infectious
and noninfectious groups. Patients with suspected infection but negative
microbiology were also excluded from the ﬁnal analysis.
Antimicrobial therapy was evaluated by 2 independent experts (EH
and JF), and it was considered appropriate if (a) the isolated pathogens
were susceptible to at least 1 of the commenced antimicrobials [15] and
(b) the appropriate dosage, as recommended by our local protocols,was
administered. Based on these results, patients were grouped post hoc
into appropriate (A group) and inappropriate (IA group) antimicrobial
treatment groups.
Patients were further divided into “medical” and “surgical” groups.
The medical group represented patients without surgical intervention.
In the surgical group, infection either was related to surgery or required
surgery for source control [16]. These groups were also further divided
into appropriate, Am(edical) and As(urgical), and inappropriate, IAm and
IAs, groups.
2.3. Protocol and data collection
When infection was suspected (based on temperature, white blood
cell count, clinical picture, PCT levels) by the attending physician, spec-
imens were sent for microbiology, and antimicrobial therapy was com-
menced. The choice of antimicrobialswas determined by local protocols
based on international guidelines [17–19].
2.3.1. Data collection
After enrollment, demographic data, parameters of vital organ func-
tions, and laboratory data were collected for 6 days. Length of ICU and
hospital stay and mortality were also documented.2.3.2. PCT measurement
Procalcitonin levels were determined immediately before the initia-
tion of antimicrobials (t0), 8 hourly (t8, t16, t24) during the ﬁrst 24 hours,
and then daily (day2-day6). The ﬂowchart of the data collection is sum-
marized in Fig. 1.
Serum PCT levels weremeasured with Cobas 6000 analyzer (Hitachi
High-Technologies Corporation, Tokyo, Japan). Analyzer reagents
(Elecsys B·R·A·H·M·S PCT assay) were developed in collaboration
with B·R·A·H·M·S Corporation (Hennigsdorf, Germany) and Roche Di-
agnostics (Mannheim, Germany). Procalcitonin was determined by
electrochemiluminescence immunoassay serum on the automated
Roche Elecsys and Cobas immunoassay analyzers.2.3.3. Microbiological staining and antibiograms
Microbiological tests were performed and sent at t0 (before the ﬁrst
antimicrobial dose was administered) and, if necessary, repeated on the
following days to identifymicroorganisms and their resistance. The type
of antimicrobials, the dosage, the bacterial strains, and their antibiogram
proﬁle were recorded.2.4. Statistical analysis
The primary end point of the study was the difference in PCT kinetics
after 24 hours of starting the antimicrobial treatment. According to our
former pilot study [20], a PCT increase of less than 70% within the ﬁrst
24 hours compared with the baseline value (t0) had an 84% positive pre-
dictive value with 80% sensitivity and 41% speciﬁcity (P= .059), indicat-
ing appropriate antimicrobial treatment. Therefore, for the study to
have 80% power to show the smallest clinically relevant difference of
15%, an increase of PCT between the A and IA groups (ie, 70% increase
in the IA group and 55% increase of PCT in the A group from t0 to t24)
with a Pb .05, the required sample size was at least 161 patients. Based
on this calculation, we decided to enroll patients for at least 12 months.
Data were analyzed using IBM SPSS Statistics Version 20 (Armonk,
NY) and Systat Software Inc SigmaPlot 12.5 (London, UK) software.
For continuous data, the Shapiro-Wilk tests were performed to assess
normal distribution. Demographic data were analyzed between groups
with the Student t test or nonparametric data with the Mann-Whitney
U test as appropriate. Biomarkers were analyzed by using 2-way
repeated-measures analysis of variances (all pairwisemultiple compar-
ison procedures: Holm-Sidakmethod). Categorical datawere compared
usingχ2 tests. Receiver operating characteristic (ROC) curve and the re-
spective areas under the curves (AUCs) were calculated for PCT and CRP
levels. The best cutoff values were determined to maximize the Youden
index (J= max[Sens + Spec − 1]). The test parameters (sensitivity,
speciﬁcity, and positive and negative predictive values) were compared
by their 95% conﬁdence intervals (CIs). A level of Pb .05 was deﬁned as
statistically signiﬁcant. Data are given as mean± standard deviation or
median (25%-75% interquartile range) as appropriate.
Table 1
Demographics and infection sources in the entire cohort
Total (N = 209) Appropriate AB (n = 108) Inappropriate AB (n = 33) P value
Age (y) 68 (19) 68 (19) 69 (20) .842
Male, n (%) 117 (56) 60 (55) 16 (48) .476
Body height (cm) 170 (12) 169 (14) 165 (19) .422
Body weight (kg) 76 (25) 70 (18) 80 (27) .218
SAPS II points 67 ± 19 68 ± 19 72 ± 16 .333
SAPS II PM 78 (47) 81 (32) 88 (27) .298
SOFA score points at t0 14 (5) 14 (4) 15 (6) .298
delta SOFA score points (t0-t24) 0 (2) 0 (2) 0 (2) .568
ICU days before enrollment 1(2) 0 (2) 1 (2) .798
ICU LOS (d) 8 (9) 8 (10) 9 (11) .263
ICU survival, n (%) 151 (72) 84 (78) 14 (42) b .001
Hospital LOS (d) 15 (17) 16 (22) 17 (16) .444
Hospital survival (%) 126 (60) 68 (63) 13 (39) .017
Mechanical ventilation (d) 4 (8) 4 (9) 7 (8) .011
Vasopressor therapy (d) 3 (4) 3 (3) 5 (4) .004
Renal replacement therapy, n (%) 65 (31) 33 (31) 19 (57) .005
Nosocomial infection, n (%) 53 (49) 16 (48) .953
Source of infection, n (%) Respiratory 54 (50) 25 (76) .007
Abdominal 19 (18) 5 (15) .744
Soft tissue 15 (14) 2 (6) .227
UTI 10 (9) 2 (6) .564
BSI 7 (6) 0 .134
Meningitis 5 (5) 0 .208
Other 1 (1) 1 (3) .371
Data are given asmedian (interquartile range) ormean±standarddeviation as appropriate. Total= infection (appropriate and inappropriate)+no infection group. Regarding the source,
a patient may have more than 1 infection at the same time. AB indicates antimicrobial therapy; n, number of patients; SAPS, Simpliﬁed Acute Physiology Score; PM, predicted mortality;
LOS, length of stay; UTI, urinary tract infection; BSI, bloodstream infection.
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Over the study period, 209 patients were enrolled. Demographics are
summarized in Table 1. From the 209 patients, 141 (67%) had proven in-
fection, with infection unproven in 44 (21%). In 24 patients, although in-
fection was highly likely, microbiology did not reveal pathogens; hence,
these subjects were excluded from the ﬁnal analysis. Procalcitonin at t0
was signiﬁcantly higher in the infectious group compared with noninfec-
tious group: 4.53 (1.76-16.30) vs 1.0 (0.13-2.98) ng/mL, P= .024, respec-
tively. In the infectious group (n = 141), 108 (77%) patients received
appropriate antimicrobial therapy (A group), and in 33 (23%), antimicro-
bials proved to be inappropriate (IA group). Detailed descriptions of the
source and pathogens are summarized in Tables S4 and S5.
Regarding demographics, there were no differences between the A
and IA groups, but ICU and hospital survival was signiﬁcantly higher
in the A group (Table 1). These patients also required less vasopressors
and renal replacement therapy compared with the IA group. From the
33 patients in the IA group, antimicrobials were changed in 20 patientsFig. 2. PCT absolute values in the entire cohort and in the medical and surgical cohort. Data are
within groups; * Pb .05 between groups.on day 2 or 3, without any signiﬁcant effect on PCT kinetics, compared
with the other 18 patients (data not shown).
3.1. PCT kinetics
In both groups, the increase in PCT levels continued after the initiation
of empirical antimicrobial treatment (t0) until 16 hours (t16) (Fig. 2A). In
the IA group, there was a signiﬁcant increase from t16 to t24, whereas in
the A group, there was a signiﬁcant decrease from t16 to t24. By t24, the
PCT reached signiﬁcantly higher levels in the IA group and remained
higher the following day compared with the A group. In the A group,
PCT levels peaked at t16, whereas in the IA group, the peak was at t24.
From t24 until the ﬁfth day, PCT levels decreased in both groups (Fig. 2A).
There was a nonsigniﬁcant increase in CRP from t0 to t24 in both
groups. In the A group, CRP peaked at t24. In the IA group, CRP remained
high on day2, with levels remaining higher compared with the A group
on days3-5. After day2, CRP levels decreased in both groups (Fig. S4A).
Body temperature showed no signiﬁcant change over time (Fig. S4B).presented as median and interquartile range. AB indicates antimicrobial therapy. #Pb .05
Fig. 3. Receiver operating characteristic curve.
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In patientswith infection, PCT followed similar kinetics inmedical (n=
91) and surgical (n=50)patients,with substantial differences in the abso-
lute values at t0 (median: 2.74 [25%-75% interquartile range: 1.30-7.72] vs
6.46 [2.61-40.07], P= .002) and at t24 (4.41 [1.52-13.55] vs 17.02 [6.74-
69.45] ng/mL, Pb .001, respectively). Medical and surgical patients were
further divided into appropriate—Am (n = 70) and As (n = 38)—and
inappropriate—IAm (n = 21) and IAs (n = 12)—subgroups. Kinetics in all
subgroups followed the same pattern as described for the whole sample
(Fig. 2B and C).
Kinetics of CRP were similar in both groups, with no signiﬁcant dif-
ferences within and between groups during the study period (Fig. S5A
and B). The same holds true for body temperature, with the only differ-
ence being that, in themedical cohort at t24, temperaturewas higher for
the next 3 days (Fig. S5C and D) (Table S3).3.3. Predictive value of PCT for indicating appropriate
antimicrobial treatment
The ROC analysis revealed that a PCT elevation from t0 to t16 had an
AUC of 0.73 (95% CI, 0.63-0.83; Pb .001) and that from t0 to t24 had an
AUC of 0.86 (95% CI, 0.77-0.94; Pb .001) (Fig. 3). According to the
Youden index, the best cutoff for PCT increase from t0 to t16 was 69.2%,
and from t0 to t24, it was 73.5% (Table 2).Table 2
Cutoff values for appropriate and inappropriate antimicrobial treatment in the entire cohort
Cutoff value Sensitivity (95% CI) Speciﬁcity (
PCT t0-t8 ≥45.6% 56.5% (0.46-0.66) 69.7% (0.51-
PCT t0-t16 ≥69.2% 65.7% (0.56-0.74) 84.8% (0.68-
PCT t0-t24 ≥73.5% 79.6% (0.70-0.86) 87.8% (0.71-
The best cutoff value was determined using the Youden index. PPV indicates positive predictiv4. Discussion
The main ﬁndings of this study were that PCT kinetics during the
ﬁrst 24 hours after commencing empirical antimicrobial therapy show
signiﬁcant differences in patients on appropriate antimicrobial therapy
compared with those on inappropriate antimicrobial therapy and that
there were signiﬁcantly higher absolute PCT values but similar kinetics
in surgical compared with medical patients with infections.
4.1. Diagnosing infection
Although the classical deﬁnitions of sepsis syndromes[21] and con-
sensus criteria of sepsis [22] have been implemented worldwide for de-
cades, differentiating systemic inﬂammatory response from bacterial
infection remains a challenge [23,24], and mortality from sepsis and
septic shock is still very high. This uncertainty in the diagnosis may
lead to unnecessary overuse of antimicrobials resulting in increased
bacterial resistance, adverse effects from the antimicrobials, and in-
creased costs [25].
In this diagnostic dilemma, there has been considerable interest in
the use of infection/sepsis biomarkers. Among these biomarkers, the
two most commonly used are PCT and CRP. Several studies have
shown that PCT has a better sensitivity and speciﬁcity for indicating bac-
terial infections than CRP [26]. This was conﬁrmed by the results from
this study, where only PCT was able to differentiate patients with prov-
en infection from patients with no infection. These results are similar to
those reported by recent large randomized trials [10,11].
4.2. Appropriate antimicrobial therapy
Inappropriate empirical antimicrobials have a strong adverse effect
on survival [27], although such therapy is a common feature in the
ICU, reportedly as high as 25% to 30% [5,15]. Once inappropriate antimi-
crobials are initiated, it often takes days (until organism isolation and
sensitivities are produced) to correct them. In our study, 23% of patients
received inappropriate antimicrobials. This high incidence may be due
to the lack of fast and reliable diagnostic tests for bacterial infections
and to the subsequent delay in microbiological results. Earlier recogni-
tion of potential inappropriatemicrobial therapymay allow anopportu-
nity to substantially improve outcome.
To our knowledge, this is the ﬁrst study to show that the early kinet-
ics of PCTmeasuredwithin theﬁrst 24 hoursmay help clinicians to eval-
uate the appropriateness of empirical antimicrobial therapy in critically
ill patients. The rationale formeasuring successive PCT levelswithin this
time frame came from the assumption that, by giving appropriate anti-
biotics, this may slow the inﬂammatory response within hours and that
this could be detected by serial measurements of PCT.
In a study by Charles et al [15], they observed a signal of lower PCT
levels on day 2 in the appropriate group, but the difference was not sig-
niﬁcant. This may be due to the fact that, in their study, PCT was mea-
sured retrospectively; therefore, the time elapsed between the PCT
measurements and the antibiotic therapy was uncontrolled, unlike
this study where investigating PCT kinetics as precisely as possible dur-
ing the ﬁrst 24 hours was a particular aim. In this study, although PCT
continued to increase after the initiation of empirical antimicrobial95% CI) PPV (95% CI) NPV (95% CI) P
0.84) 31.7% (0.28-0.54) 85.4% (0.78-0.92) .090
0.94) 42.1% (0.33-0.60) 92.8% (0.82-0.95) .048
0.96) 53.5% (0.41-0.70) 95.2% (0.84-0.98) b .001
e value; NPV, negative predictive value.
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group, there was a signiﬁcant PCT decrease during the next 8 hours
(t24), whereas in the IA group, PCT continued to increase, reached a sig-
niﬁcantly higher level by t24, and remained higher the next day com-
pared with the A group. A PCT increase of at least 69.2% during the
ﬁrst 16 hours or a PCT increase of at least 73.5% during the ﬁrst 24
hours was the best cutoff value to indicate inappropriate antimicrobial
treatment. It is known that PCT increases within hours after an infec-
tious insult and levels halve daily once the infection is under control
[28]. This feature explains the signiﬁcant difference found in the PCT ki-
netics between the A and IA groups during the ﬁrst 24 hours. It is also
important to note that, after day 1, PCT decreased in both groups, al-
though PCT levels remained signiﬁcantly higher in the IA group. This
is in linewith the results fromCharles et al [15], whomeasured PCT dur-
ing the ﬁrst 4 days of treatment and found a decrease from day 2 to day
3 in both the appropriate and inappropriate groups, but the decrease
was more pronounced in the appropriate group. This can be explained
by the ﬁnding that adequate supportive therapy on its own may atten-
uate the inﬂammatory response [29]. Furthermore, monocytes become
exhausted after a certain period of time, also affecting PCT production
[30,31]. It may be of signiﬁcance that the groupingwas based on the ini-
tial antibiotic therapy; hence, no patients were “crossed over” from the
inappropriate to the appropriate group. However, from the 33 patients
in the IA group, antibiotics were changed on day 2 or day 3 in 18
cases. We analyzed and compared PCT kinetics in patients in whom
we changed (n = 18) as compared with patients in whom we did not
change (n= 15) antibiotics over the study period but found no signiﬁ-
cant differences (data not shown).
Translating the results of the current study into clinical practice
means that, when measuring PCT on commencement of antimicrobials
(t0) and then at 16 and 24 hours, a “large” increase within the ﬁrst 16 to
24 hours (≥69.2%-73.5%) may indicate inappropriate antimicrobial
therapy, whereas a lower-grade increase or a decreasing tendency
after 16 hours would support appropriate antimicrobial therapy. The
clinical importance of our ﬁndings is emphasized by the signiﬁcant dif-
ference in hospital mortality between the A group and the IA group
(37% vs 61%).
Another important ﬁnding of the current study is that CRP did not
differentiate between the appropriate and inappropriate groups within
the ﬁrst 48 hours. This is in accordance with previously published data
indicating that CRP is a “slow”marker and not as reliable as PCT in the
critically ill [32,33]. The same holds true for body temperature, which,
as with other studies, highlights that its use for guiding antimicrobial
therapy is questionable [23].4.3. PCT kinetics in surgical as compared with medical patients
Our results also support that PCT is several times higher in surgical
compared with medical patients, but we also found that early kinetics
were similar to those found in the whole sample. Our data also suggest
that percentage changes of PCT may be a better, universally applicable
approach for monitoring treatment progress rather than absolute
values.
There is strong evidence that, because of direct cellular damage as in
severe trauma, major surgery, and after ischemia-reperfusion, also
known as damage-associatedmolecular patterns, there is an inﬂammato-
ry mediator release very similar to that following an infectious insult,
called pathogen-associated molecular patterns (PAMPs) [34]. Therefore,
unspeciﬁc elevations in PCT levels can typically be seen in the absence
of a bacterial infection [33,35]. Theoretically, in surgical patients with
sepsis, damage-associated molecular pattern and PAMP take place at
the same time, leading to a pronounced inﬂammatory response, where-
as inmedical patients, PAMPmay occur on its own, resulting in a less ex-
tensive inﬂammatory response [16]. This feature is the reason why the
same absolute values of PCT may mean completely differentinformation in a medical compared with a surgical patient but, as
shown in our results, kinetics follow a uniform pattern.
4.4. Limitations of the study
The most important limitation for us during the analysis of the re-
sults was the lack of criterion standard for diagnosing infection. Al-
though we attempted to reduce the potential error in judgment by
allocating patients into each group by 2 independent experts blinded
for PCT kinetics in a post hoc fashion taking all clinical andmicrobiology
data into account, one cannot exclude that mistakes may have still ap-
peared in the process. Furthermore, the power analysis sample size
could have been larger to detect a stronger signal, so a multicenter de-
sign would have been better. In addition, because of the exclusions,
the sample size eventually included in the ﬁnal analysis (141 patients)
was substantially less than that calculated in the power analysis. It
may also be important to note the uneven proportion of patients in
the appropriate and inappropriate groups (75% vs 25%), a general limi-
tation of every study in this ﬁeld, which may also have affected our re-
sults. Finally, the clinical impact of our ﬁndings will have to be tested
in a prospective randomized trial to see whether tailoring empirical an-
timicrobial therapy to PCT kinetics has any effect on outcome.
5. Conclusion
In this study, PCTkineticswithin theﬁrst 24hours after commencing
empirical antimicrobial therapy showed a signiﬁcant increase in
patients in whom therapy proved to be inappropriate, whereas in the
appropriate group, after a brief increase at 16 hours, there was a signif-
icant decrease by 24 hours. Applying this approach may be helpful in
quickly tailoring antimicrobial therapy for the patient's speciﬁc needs.
However, the clinical relevance of this “PCT kinetics–guided approach”
should be conﬁrmed in a prospective randomized fashion.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jcrc.2016.04.007.
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